Dr. Lerner opened his presentation by discussing the SWOG S1011 trial, a randomized clinical study evaluating the benefit of limited versus extended pelvic lymph node dissection at the time of radical ...

Dr. Jonathan Rosenberg discussed the CALGB 90601 study and titled his talk: From lemons to lemonade, possibilities from negative cooperative group trials. Dr. Rosenberg began by highlighting one of ...

Alan Bryce interviews Tanya Dorff about recommendations from the 2024 US Prostate Cancer Consensus Conference addressing clinical gray areas in prostate cancer management.

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

Zachary Klaassen hosts Andrew Hahn to discuss future directions in metastatic castration-resistant prostate cancer. Dr. Hahn highlights the "golden era" for targeting cell surface proteins through ...

Alan Bryce hosts Mary-Ellen Taplin to discuss key recommendations from the 2024 US Prostate Cancer Consensus Conference addressing biochemical recurrence management. Dr. Taplin emphasizes that PSMA ...

HIF-2 inhibitor kidney cancer, Casdatifan cabozantinib combination, refractory renal cell carcinoma treatment, AB-521 clinical trial, clear cell RCC therapy, Combination HIF-2α/VEGF Dual Inhibition in ...

CHAI biomarker, using AI to predict BCG vs Gem/Doce response in bladder cancer, achieving 90% success rate, insights on precision medicine, Computational Histology AI Guides Treatment Selection for ...

ENZAMET study, IGF-1 cytokines and sphingolipids as prognostic factors in mHSPC, precision metabolic therapy trials, Exploring IGF-1 Pathway Biomarkers and Outcomes in Metastatic Hormone-Sensitive ...

In [18F]F-PSMA-1007 PET imaging, focal bone uptake without morphological correlate (MC) on CT, is often classified as benign. In [68Ga]Ga-PSMA-11, intense focal uptake without MC in a classical ...

analysis of 3 key urothelial cancer studies, ASCO 2025, EVP complete responses and potential cures, Advances in Urothelial Cancer Treatment: Efficacy, Toxicity, and Unanswered Questions with ...

Previous research on Radium-223 treatment patterns in metastatic prostate cancer has been limited to select sites, oncology practices, or claims databases. Limited data exists on the use and outcomes ...